Previous 10 | Next 10 |
home / stock / blu:cc / blu:cc news
Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with anticipated regulatory approval and launch in 2...
Tech stocks lifted the S&P 500 into the green Thursday as the market attempted to wrap up the short trading week on a high note. The Dow Jones Industrials, after most of the day in negative territory, squeezed out gains of 2.63 points to 33,485.35. The S&P 500 moved ahead 14.61 po...
Once-daily Extended-Release formulation demonstrated equivalent bioavailability to twice-daily Immediate Release formulation Extended-Release formulation was well tolerated, with the safety profile consistent with previous camlipixant trials and no taste-related adverse events reporte...
- Patient enrollment ongoing in the CALM Phase 3 program with topline data expected for CALM-1 in the second half of 2024 - - Ended year with US$337.1 million in cash, cash equivalents and short-term investments; cash runway extends to the second half of 2025 and through expected ...
2023-03-06 12:30:00 ET Most biotech stocks have low visibility with investors because the risks are pretty high. Nonetheless, the TSX has several names worth watching in 2023. Bausch Health ( TSX:BHC ) has appreciated substantially from year-end 2022, and three more could break ...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today...
2022 was a rough year for Canadian stocks, with most losing value throughout the year. There were only a handful of non-energy stocks on the TSX that managed to gain value through 2022 and even fewer small-cap stocks. A small-cap stock is defined as any company with a market cap between $...
Healthcare stocks aren’t attractive to investors in 2022. The selloff is more severe than information technology, given the sector’s year-to-date loss of nearly 51%. Moreover, underperforming cannabis stocks like Canopy Growth , Tilray , and Cronos Group are among th...
Biotech companies are often at the cutting edge of medical research, making them relatively risky but profitable investments. Yet, the prospects can be dramatically different for each biotech company. Many new ventures fail even before entering the market, resulting in millions of dollars i...
News, Short Squeeze, Breakout and More Instantly...
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON , June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed ...
2023-06-27 18:45:00 ET Early investors in Canadian biotech stock BELLUS Health ( TSX:BLU ) could be ecstatic right now after a fine 75.5% rally in BLU stock year to date. The bullish run was ensued after global pharmaceuticals giant GSK offered to acquire all BELLUS stock at...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced the positive outcome of the BELLUS shareholders (“ Shareholders ”) vote at this morning’s special meeting of the Shareholders (the “ ...